Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4538HSC in pediatric malignant solid tumors and epithelioid sarcoma
jRCT2031260289Phase 2Recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in Non-hematologic malignancy and epithelioid sarcoma (ES) (3 cohorts), sponsored by Ono Pharmaceutical. Primary endpoints: Tolerability and safety and Efficacy. Started Sep 2026; status: recruiting.
02
Drugs
03
Conditions
Non-hematologic malignancyepithelioid sarcoma (ES)
Beyond the preview
Go deeper on jRCT2031260289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260289.